



SR1281

LRB102 29291 MST 41255 r

1

SENATE RESOLUTION

2           WHEREAS, The substance use and opioid use crises in  
3 Illinois are responsible for historically high rates of  
4 overdoses and overdose-related fatalities; and

5           WHEREAS, According to the State's own opioid data, use and  
6 misuse of opioids in Illinois also continues to have  
7 substantial associated public health consequences, including  
8 increased rates of infectious diseases such as hepatitis C and  
9 HIV, lost productivity in the workplace, crime, neonatal  
10 abstinence syndrome, and homelessness; and

11           WHEREAS, The purpose of many federal programs is to  
12 provide resources to states for increasing access to  
13 FDA-approved medications for the treatment of substance use  
14 and opioid use disorder and for supporting the continuum of  
15 prevention, harm reduction, treatment, and recovery support  
16 services for opioid use disorder and other substance use  
17 disorders; and

18           WHEREAS, A prescription digital therapeutic is approved,  
19 cleared, or classified by the Food and Drug Administration  
20 under section 510(k), 513(f), or 515 of the Federal Food,  
21 Drug, and Cosmetic Act, and requires a prescription under  
22 section 801.109 of title 21 of the Code of Federal Regulations

1 (or any successor regulation); and

2 WHEREAS, Prescription digital therapeutics have the  
3 potential to significantly improve health care delivery to  
4 underserved populations because they transcend care access  
5 limitations due to geography, socioeconomic status, trust of  
6 traditional institutions, and more; and

7 WHEREAS, Clinical studies have shown significantly greater  
8 odds of stimulant and opioid abstinence during treatment if  
9 treatment as usual is combined with an FDA-authorized PDT that  
10 has both cognitive behavioral therapy and contingency  
11 management; and

12 WHEREAS, A 2018 study demonstrated that when a Community  
13 Reinforcement Approach and Contingency Management are  
14 administered together then a patient is 2.84 times more likely  
15 to remain abstinent at the end of the treatment than those in  
16 other programs; and

17 WHEREAS, The White House's Office of National Drug Control  
18 Policy recently released its 2022 National Drug Control  
19 Strategy document; specifically, the document points to  
20 prescription digital therapeutics and how these tools could  
21 help increase services for a wide array of patients; and

1           WHEREAS, Federally-funded programs help many states to  
2 fund access to FDA-authorized PDTs for patients and providers;  
3 therefore, be it

4           RESOLVED, BY THE SENATE OF THE ONE HUNDRED SECOND GENERAL  
5 ASSEMBLY OF THE STATE OF ILLINOIS, that we urge the Department  
6 of Human Services and the Governor's Opioid Overdose  
7 Prevention and Recovery Steering Committee to closely consider  
8 funding FDA-authorized PDTs to help patients who are  
9 struggling with substance use and opioid use disorders; and be  
10 it further

11           RESOLVED, That a suitable copy of this resolution be  
12 delivered to the Secretary of the Illinois Department of Human  
13 Services.